Cargando…
ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
Purpose: To develop a qPCR method to examine the 202 isoform of excision repair cross-complementation group 1 (ERCC1_202) and to evaluate its clinical utility as a predictive biomarker for platinum-based chemotherapy in non-small cell lung cancer (NSCLC). Methods: The relative complementary DNA (cDN...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604217/ https://www.ncbi.nlm.nih.gov/pubmed/28928874 http://dx.doi.org/10.7150/jca.19897 |
_version_ | 1783264831358369792 |
---|---|
author | Wang, Xiyong Zhu, Xiaoli Zhang, Hongming Fan, Xiaobo Xue, Xiulei Chen, Yan Ding, Chenbo Zhao, Jianwen Wu, Guoqiu |
author_facet | Wang, Xiyong Zhu, Xiaoli Zhang, Hongming Fan, Xiaobo Xue, Xiulei Chen, Yan Ding, Chenbo Zhao, Jianwen Wu, Guoqiu |
author_sort | Wang, Xiyong |
collection | PubMed |
description | Purpose: To develop a qPCR method to examine the 202 isoform of excision repair cross-complementation group 1 (ERCC1_202) and to evaluate its clinical utility as a predictive biomarker for platinum-based chemotherapy in non-small cell lung cancer (NSCLC). Methods: The relative complementary DNA (cDNA) quantification for ERCC1_202 was conducted using a fluorescence-based, real-time detection method and β-actin was used as a reference gene. Results: A strong correlation was observed between ERCC1_202 mRNA and ERCC1 mRNA levels in NSCLC cells (P < 0.001). 28 patients completed this research. Our results implied that as ERCC1_202 levels increased, the risk of progression (HR = 4.296, P = 0.011) and death (HR = 6.503, P = 0.001) increased. At multivariate analysis, high expression of ERCC1_202 was shown to be an independent predictive factor for time to progression (P = 0.047), and progression-free survival (P = 0.014). However, the high expression of ERCC1_202 was not an independent predictive factor for response (P = 0.324). Conclusions: This study suggests that the efficacy of platinum-based chemotherapy can be improved when customized according to the expression of ERCC1_202. |
format | Online Article Text |
id | pubmed-5604217 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-56042172017-09-19 ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy Wang, Xiyong Zhu, Xiaoli Zhang, Hongming Fan, Xiaobo Xue, Xiulei Chen, Yan Ding, Chenbo Zhao, Jianwen Wu, Guoqiu J Cancer Research Paper Purpose: To develop a qPCR method to examine the 202 isoform of excision repair cross-complementation group 1 (ERCC1_202) and to evaluate its clinical utility as a predictive biomarker for platinum-based chemotherapy in non-small cell lung cancer (NSCLC). Methods: The relative complementary DNA (cDNA) quantification for ERCC1_202 was conducted using a fluorescence-based, real-time detection method and β-actin was used as a reference gene. Results: A strong correlation was observed between ERCC1_202 mRNA and ERCC1 mRNA levels in NSCLC cells (P < 0.001). 28 patients completed this research. Our results implied that as ERCC1_202 levels increased, the risk of progression (HR = 4.296, P = 0.011) and death (HR = 6.503, P = 0.001) increased. At multivariate analysis, high expression of ERCC1_202 was shown to be an independent predictive factor for time to progression (P = 0.047), and progression-free survival (P = 0.014). However, the high expression of ERCC1_202 was not an independent predictive factor for response (P = 0.324). Conclusions: This study suggests that the efficacy of platinum-based chemotherapy can be improved when customized according to the expression of ERCC1_202. Ivyspring International Publisher 2017-08-23 /pmc/articles/PMC5604217/ /pubmed/28928874 http://dx.doi.org/10.7150/jca.19897 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Wang, Xiyong Zhu, Xiaoli Zhang, Hongming Fan, Xiaobo Xue, Xiulei Chen, Yan Ding, Chenbo Zhao, Jianwen Wu, Guoqiu ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy |
title | ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy |
title_full | ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy |
title_fullStr | ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy |
title_full_unstemmed | ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy |
title_short | ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy |
title_sort | ercc1_202 is a prognostic biomarker in advanced stage non-small cell lung cancer patients treated with platinum-based chemotherapy |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604217/ https://www.ncbi.nlm.nih.gov/pubmed/28928874 http://dx.doi.org/10.7150/jca.19897 |
work_keys_str_mv | AT wangxiyong ercc1202isaprognosticbiomarkerinadvancedstagenonsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy AT zhuxiaoli ercc1202isaprognosticbiomarkerinadvancedstagenonsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy AT zhanghongming ercc1202isaprognosticbiomarkerinadvancedstagenonsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy AT fanxiaobo ercc1202isaprognosticbiomarkerinadvancedstagenonsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy AT xuexiulei ercc1202isaprognosticbiomarkerinadvancedstagenonsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy AT chenyan ercc1202isaprognosticbiomarkerinadvancedstagenonsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy AT dingchenbo ercc1202isaprognosticbiomarkerinadvancedstagenonsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy AT zhaojianwen ercc1202isaprognosticbiomarkerinadvancedstagenonsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy AT wuguoqiu ercc1202isaprognosticbiomarkerinadvancedstagenonsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy |